Bayer's Off-Label Yaz Marketing Violated FCA: Watchdog

Law360, New York (December 14, 2011, 4:57 PM EST) -- A pharmaceutical company watchdog accused Bayer Schering Pharma AG of marketing its Yasmin and Yaz contraceptives for unapproved purposes and causing doctors to seek Medicaid reimbursements for off-label prescriptions of those drugs, according to court documents unsealed Monday.

In a complaint filed under seal in October 2010 in Texas federal court, relator Pharma Fraud Watch LLC alleges that Bayer violated the False Claims Act by knowingly causing pharmacists and doctors to file false federal government claims by marketing Yaz and Yasmin for uses the U.S. Food...
To view the full article, register now.

Documents

Related

Sections

Case Information

Case Title

USA v. Bayer Schering Pharma AG, et al.,


Case Number

1:10-cv-00669

Court

Texas Eastern

Nature of Suit

Other Statutory Actions

Judge

Marcia A. Crone

Date Filed

October 22, 2010

Law Firms

Companies

Government Agencies

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.